Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the psoriasis longitudinal assessment and registry (PSOLAR)

JAMA Dermatology

Volumn 151, Issue 9, 2015, Pages 961-969

  Kalb, Robert E ^a   Fiorentino, David F ^b   Lebwohl, Mark G ^c   Toole, John ^d   Poulin, Yves ^e   Cohen, Arnon D ^f   Goyal, Kavitha ^g   Fakharzadeh, Steven ^g   Calabro, Stephen ^g   Chevrier, Marc ^h   Langholff, Wayne ^h   You, Yin ^h   Leonardi, Craig L ⁱ  

^a UNIVERSITY AT BUFFALO   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g Janssen Pharmaceutical Companies of Johnson Johnson   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PSORALEN; RETINOID; USTEKINUMAB; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT;

ABSCESS; ADULT; ADVERSE OUTCOME; AGING; APPENDICITIS; ARTICLE; BIOLOGICAL THERAPY; BODY MASS; BRONCHITIS; CELLULITIS; CLINICAL PRACTICE; COHORT ANALYSIS; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DIVERTICULITIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GASTROENTERITIS; HERPES ZOSTER; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; INFLUENZA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; NECROTIZING FASCIITIS; OSTEOMYELITIS; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PYELONEPHRITIS; SEPSIS; SEX DIFFERENCE; SKIN INFECTION; SMOKING HABIT; SYSTEMIC THERAPY; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND INFECTION; AGED; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MIDDLE EAST; MULTICENTER STUDY; NORTH AMERICA; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOUTH AND CENTRAL AMERICA; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL PRODUCTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; LATIN AMERICA; MALE; MIDDLE AGED; MIDDLE EAST; NORTH AMERICA; PREVALENCE; PSORIASIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84930342599     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.0718     Document Type: Article

References (25)

1. Papp KA, Griffiths CE, Gordon K, et al; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844-854.
2. Reich K, Wozel G, Zheng H, van Hoogstraten HJ, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325-1334.
3. Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12(5):321-337.
4. Pariser DM, Leonardi CL, Gordon K, et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J AmAcad Dermatol. 2012;67(2):245-256.
5. Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol. 2012;167(suppl 3):3-11.
6. Garcia-Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463-470.
7. Tan X, Balkrishnan R, Feldman SR. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis. J Drugs Dermatol. 2013;12(3): e41-e45.
8. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J AmAcad Dermatol. 2011;64(6):1035-1050.
9. Galloway JB, Hyrich KL, Mercer LK, et al; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124-131.
10. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of theWorld Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011;106(9):1594-1602.
11. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72(4): 517-524.
12. Papp KA, Strober B, Augustin M, Calabro S, Londhe A, ChevrierM; PSOLAR Investigators and Steering Committee. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11(10):1210-1217.
13. Dogra S, Mahajan R. Systemicmethotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol. 2013;38(6):573-588.
14. Magill SS, Edwards JR, Bamberg W, et al; Emerging Infections Program Healthcare- Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198-1208.
15. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306(21):2331-2339.
16. Menter A, Williams DA, Thaci D, Teixeira H, Bereswill M. ESPRIT: year to year safety over 4 years of interim results from a 10-year postmarketing surveillance registry of adalimumab for moderate to severe psoriasis. J AmAcad Dermatol. 2014;70(5, suppl 1):P7929.
17. Kimball AB, Pariser D, Yamauchi PS, et al. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J AmAcad Dermatol. 2013; 68(5):756-764.
18. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896-2904.
19. van Dartel SA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013;72(6):895-900.
20. Kimball AB, Leonardi C, Stahle M, et al; PSOLAR Steering Committee. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171(1):137-147.
21. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J AmAcad Dermatol. 2008; 58(5):826-850.
22. Canadian Dermatology Association. Canadian guidelines for the management of plaque psoriasis. http://www.dermatology.ca/guidelines. Accessed November 26, 2014.
23. Smith CH, Anstey AV, Barker JN, et al; Chair of Guideline Group. British Association of Dermatologists' guidelines for biologic interventions for psoriasis. Br J Dermatol. 2009;161 (5):987-1019.
24. Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13(12): 1441-1448.
25. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry. J Drugs Dermatol. [In Press].